Skip to main content
. 2022 Sep 19;6:66. doi: 10.1038/s41698-022-00301-8

Table 1.

Clincal demograchics of enrolled patients regarding MPR status.

Characteristics All patients (N = 40) Patients with major pathological response (N = 15) Patients without major pathological response (N = 25) P-value
Age —— yrs 0.812
Mean ± SD 58.7 ± 10.9 58.6 ± 9.9 58.7 ± 11.5
Median (range) 61 (25–75) 60 (36–72) 62 (25–75)
Gender —— no. (%) 0.740
Female 16 (40.0) 5 (28.6) 11 (44.0)
Male 24 (60.0) 10 (71.4) 14 (56.0)
Smoking status —— no. (%) 0.749
Never 23 (57.5) 8 (53.3) 15 (60.0)
Former/current 17 (42.5) 7 (46.6) 10 (40.0)
Clinical stage —— no. (%) 0.580
II 10 (25.0) 5 (35.7) 5 (20.0)
IIIA 22 (55.0) 7 (50.0) 15 (60.0)
IIIB-IVA 8 (20.0)* 3 (14.3) 5 (20.0)
Mutation features —— no. (%) 0.587
EGFR alteration 19 (47.5) 8 (50.0) 11 (44.0)
KRAS alteration 9 (22.5) 4 (28.6) 5 (20.0)
Other mutations 12 (30.0) 3 (21.4) 9 (36.0)
PD-L1 expression——no. (%) 0.208
Negative 9 (22.5) 4 (26.7) 5 (20.0)
1–49% 7 (17.5) 2 (13.3) 5 (20.0)
≥50% 15 (37.5) 8 (53.3) 7 (28.0)
Unknown 9 (22.5) 1 (6.7) 8 (32.0)

*One patient with suspected left adrenal gland metastatsis was included which dismissed after neoadjuvant immunotherapy plus chemotherapy.